15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Ligand Pharmaceuticals Incorporated, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $220.00 to $388.00, a moderate spread. The average target of $319.00 sits 8% above the current $296.69. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.56 next quarter toward $11.83 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Ligand Pharmaceuticals Incorporated.
As of Jul, 7 of 7 firms rate LGND a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LGND EPS & revenue forecast
EPS · NEXT QUARTER
$2.56
Range $2.33 – $2.88 · 8 analysts · -17% YoY
Next period, 8 analysts expect Ligand Pharmaceuticals Incorporated to earn $2.56 a share (range $2.33 – $2.88), versus $3.09 a year earlier. Full-year consensus is $9.18, growing to $11.83 the year after.
REVENUE · NEXT QUARTER
$81.0M
Range $69.2M – $92.4M · 8 analysts · -30% YoY
Revenue is expected to reach $81.0M (range $69.2M – $92.4M), -29.8% year-over-year. Full-year consensus is $289.8M, rising to $375.4M next year.
Top analysts covering Ligand Pharmaceuticals Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LGND.
#1
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$387.00+30.4% to target
Overall win rate
43%
+ Follow
#2
Balaji Prasad
Barclays · Rank #147
Buy
$160.00-46.1% to target
Overall win rate
44%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #254
Buy
$277.00-6.6% to target
Overall win rate
37%
+ Follow
#4
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$220.00-25.8% to target
Overall win rate
39%
+ Follow
#5
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$289.00-2.6% to target
Overall win rate
32%
+ Follow
LGND stock forecast FAQ
What is LGND's average 12-month price target?+
The 7 analysts with a live target average $319.00 for Ligand Pharmaceuticals Incorporated over the next 12 months, ranging from a $388.00 high to a $220.00 low.
Is LGND stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LGND?+
The Street-high target is $388.00 (B of A Securities), and the Street-low is $220.00 (Benchmark). The average of all 7 active targets is $319.00.
How many Wall Street analysts cover LGND?+
7 analysts have an active rating on Ligand Pharmaceuticals Incorporated, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering LGND?+
Among analysts who currently cover LGND, Yigal Nochomovitz of Citigroup has the strongest overall Quantellect track record (Rank #131). Their current call is Buy with a $387.00 target.
What is Ligand Pharmaceuticals Incorporated's projected EPS for next quarter?+
The consensus estimate is $2.56 per share (range $2.33 – $2.88) across 8 analysts. Full-year EPS is projected at $9.18, rising to $11.83 the following year.
How much revenue is Ligand Pharmaceuticals Incorporated expected to report next quarter?+
Consensus revenue is $81.0M (range $69.2M – $92.4M). Full-year revenue is projected at $289.8M, growing to $375.4M next year.
Have analysts been upgrading or downgrading LGND lately?+
As of Jul, 7 of 7 firms rate LGND a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LGND calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
